GHRH analogue
Also known as: Sermorelin acetate · GRF 1-29 · GHRH 1-29
The essentials at a glance
Stimulates GHRH-receptor signalling. There is currently no generally marketed FDA/EMA-approved sermorelin medicine.
Distinction: Sermorelin is a short GHRH fragment that stimulates the body's own hormone release, rather than directly replacing growth hormone like somatropin.
Prohibited or covered under WADA rules in competitive sport.
The substance is currently being studied in structured human clinical trials, but a general approval does not yet exist.
Not FDA/EMA approved: No FDA- or EMA-approved medicinal product; efficacy and safety are not established.
Research questions
This examines whether a growth hormone-releasing hormone analogue prompts the pituitary gland to release its own growth hormone, like a signal instructing the gland to release. Researchers measure growth hormone and IGF-1 levels in blood.
This studies how much growth hormone the pituitary gland releases into the blood after a stimulus, similar to measuring how much water flows out when a tap is briefly opened. Researchers typically draw blood samples at several time points to capture the size and timing of the release.
Researchers study how a substance amplifies the natural hormone chain from brain to pituitary to growth hormone, rather than supplying growth hormone directly. Hormone levels over time and muscle or fat mass are measured.
Simple example
Think of it like a component still being tested in a development workshop, not yet cleared for general use.
Research status means efficacy, dosing, and safety in humans are not yet conclusively established.
Community themes
Personal experience reports and vendor marketing from communities are not scientific proof of efficacy.
Combinations of growth-axis, mitochondrial, and skin peptides are compared here with the goal of influencing visible or felt signs of ageing, often documented personally over years. Anecdotes and vendor advertising about slowed ageing are not scientific proof.
Here, muscle growth, strength gains, and recovery times are compared between different growth and repair peptides, often based on personal training logs. Vendor and user claims about muscle gains are anecdotal experience, not controlled study results.
Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.
Why individual profiles do not contain mixing instructions
Reconstitution depends on the exact product, label, identity, concentration, sterility and stability. Arithmetic examples appear only in the separately labelled community area and are not recommendations.
Reconstitution & quantitiesOpen basics, units and sourcesUse & mixingEvidence boundary
There is currently no generally marketed FDA/EMA-approved sermorelin medicine.
No peptide sales or individual recommendations. A separately labelled community area documents third-party protocol claims without medically endorsing them.
Primary sources
Regulators, trial registries and scientific databases support the classification and carry more weight than vendor or community claims.
